Cargando…
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
INTRODUCTION: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335513/ https://www.ncbi.nlm.nih.gov/pubmed/25888060 http://dx.doi.org/10.1186/s13054-015-0758-3 |
_version_ | 1782358357636546560 |
---|---|
author | Sinnollareddy, Mahipal G Roberts, Jason A Lipman, Jeffrey Akova, Murat Bassetti, Matteo De Waele, Jan J Kaukonen, Kirsi-Maija Koulenti, Despoina Martin, Claude Montravers, Philippe Rello, Jordi Rhodes, Andrew Starr, Therese Wallis, Steven C Dimopoulos, George |
author_facet | Sinnollareddy, Mahipal G Roberts, Jason A Lipman, Jeffrey Akova, Murat Bassetti, Matteo De Waele, Jan J Kaukonen, Kirsi-Maija Koulenti, Despoina Martin, Claude Montravers, Philippe Rello, Jordi Rhodes, Andrew Starr, Therese Wallis, Steven C Dimopoulos, George |
author_sort | Sinnollareddy, Mahipal G |
collection | PubMed |
description | INTRODUCTION: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this cohort of intensive care unit patients. METHODS: The Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by critically ill patients administered fluconazole (n = 15), anidulafungin (n = 9), and caspofungin (n = 7). Three blood samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a noncompartmental approach. RESULTS: The mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the included patients were 58 years, 84 kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target, ratio of free drug area under the concentration-time curve from 0 to 24 hours to minimum inhibitory concentration (fAUC(0–24)/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly associated with achievement of fAUC(0–24)/MIC ≥100 (P = 0.0003). CONCLUSIONS: Considerable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin. A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to minimize variability. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-0758-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4335513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43355132015-02-21 Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study Sinnollareddy, Mahipal G Roberts, Jason A Lipman, Jeffrey Akova, Murat Bassetti, Matteo De Waele, Jan J Kaukonen, Kirsi-Maija Koulenti, Despoina Martin, Claude Montravers, Philippe Rello, Jordi Rhodes, Andrew Starr, Therese Wallis, Steven C Dimopoulos, George Crit Care Research INTRODUCTION: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this cohort of intensive care unit patients. METHODS: The Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by critically ill patients administered fluconazole (n = 15), anidulafungin (n = 9), and caspofungin (n = 7). Three blood samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a noncompartmental approach. RESULTS: The mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the included patients were 58 years, 84 kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target, ratio of free drug area under the concentration-time curve from 0 to 24 hours to minimum inhibitory concentration (fAUC(0–24)/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly associated with achievement of fAUC(0–24)/MIC ≥100 (P = 0.0003). CONCLUSIONS: Considerable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin. A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to minimize variability. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-0758-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-04 2015 /pmc/articles/PMC4335513/ /pubmed/25888060 http://dx.doi.org/10.1186/s13054-015-0758-3 Text en © Sinnollareddy et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sinnollareddy, Mahipal G Roberts, Jason A Lipman, Jeffrey Akova, Murat Bassetti, Matteo De Waele, Jan J Kaukonen, Kirsi-Maija Koulenti, Despoina Martin, Claude Montravers, Philippe Rello, Jordi Rhodes, Andrew Starr, Therese Wallis, Steven C Dimopoulos, George Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study |
title | Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study |
title_full | Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study |
title_fullStr | Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study |
title_full_unstemmed | Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study |
title_short | Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study |
title_sort | pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (dali) patients study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335513/ https://www.ncbi.nlm.nih.gov/pubmed/25888060 http://dx.doi.org/10.1186/s13054-015-0758-3 |
work_keys_str_mv | AT sinnollareddymahipalg pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT robertsjasona pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT lipmanjeffrey pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT akovamurat pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT bassettimatteo pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT dewaelejanj pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT kaukonenkirsimaija pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT koulentidespoina pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT martinclaude pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT montraversphilippe pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT rellojordi pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT rhodesandrew pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT starrtherese pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT wallisstevenc pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT dimopoulosgeorge pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy AT pharmacokineticvariabilityandexposuresoffluconazoleanidulafunginandcaspofungininintensivecareunitpatientsdatafrommultinationaldefiningantibioticlevelsinintensivecareunitdalipatientsstudy |